Alpine Woods Capital Investors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Alpine Woods Capital Investors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-6,000	Closed	-$309K	–	472
2015 Q4	$309K	Sell	6,000 -3,000	-33%	-$145K	0.02%	370
2015 Q3	$384K	Hold	9,000	–	–	0.02%	354
2015 Q2	$410K	Buy	+9,000	New	+$362K	0.02%	339

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alpine Woods Capital Investors's PTLA Position: Q1 2016 in Review

Alpine Woods Capital Investors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2016, closing a stake of 6,000 shares — an estimated $309K sold.

Alpine Woods Capital Investors first reported a position in PTLA in Q2 2015 and held it in 3 quarters. The position peaked at $410K in Q2 2015. 167 funds tracked by Wall St. Rank hold PTLA as of Q1 2016.

Alpine Woods Capital Investors reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Alpine Woods Capital Investors sold 6,000 Portola Pharmaceuticals, Inc. shares in Q1 2016, an estimated $309K.
Alpine Woods Capital Investors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2015 and held it in 3 quarters.
Alpine Woods Capital Investors's Portola Pharmaceuticals, Inc. position peaked at $410K in Q2 2015.
167 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2016.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2016, filed 9 May 2016.